

BENTLEY PHARMACEUTICALS INC

Form 10-Q

May 09, 2007

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2007

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the transition period from

to

Commission File Number 1-10581

Bentley Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

DELAWARE

(State or other jurisdiction of
incorporation or organization)

No. 59-1513162

(I.R.S. Employer
Identification No.)

Bentley Park, 2 Holland Way, Exeter, New Hampshire 03833

(Current Address of Principal Executive Offices)

Registrant's telephone number, including area code: **(603) 658-6100**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES NO

The number of shares of the registrant's common stock outstanding as of May 9, 2007 was 22,273,399.

Bentley Pharmaceuticals, Inc. and Subsidiaries
Form 10-Q for the Quarter Ended March 31, 2007
Index

| | Page |
|--|-------------|
| Part I. Unaudited Financial Information | |
| Item 1. Condensed Consolidated Financial Statements: | |
| <u>Consolidated Balance Sheets as of March 31, 2007 and December 31, 2006</u> | 3 |
| <u>Consolidated Income Statements for the three months ended March 31, 2007 and 2006</u> | 4 |
| <u>Consolidated Statement of Changes in Stockholders' Equity for the three months ended March 31, 2007</u> | 5 |
| <u>Consolidated Statements of Cash Flows for the three months ended March 31, 2007 and 2006</u> | 6 |
| <u>Notes to Condensed Consolidated Financial Statements</u> | 8 |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 17 |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u> | 27 |
| Item 4. <u>Controls and Procedures</u> | 27 |
| Part II. Other Information | |
| <u>Item 6. Exhibits</u> | 28 |
| EX-3.1 Restated Certification of Incorporation dated, October 29, 1999 | |
| EX-3.2 Certificate of Designation of Series A Junior Participating Preferred Stock | |
| EX-31.1 Section 302 Certification of C.E.O. | |
| EX-31.2 Section 302 Certification of C.F.O. | |
| EX-32.1 Section 906 Certification of C.E.O. | |
| EX-32.2 Section 906 Certification of C.F.O. | |

Table of Contents**Bentley Pharmaceuticals, Inc. and Subsidiaries
Consolidated Balance Sheets**

| <i>(in thousands, except per share data)</i> | March 31, 2007 | December 31, 2006 |
|---|---------------------------|----------------------------------|
| <u>Assets</u> | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 20,081 | \$ 12,424 |
| Marketable securities | 524 | 3,177 |
| Receivables, net | 33,496 | 32,963 |
| Inventories | 16,650 | 16,279 |
| Deferred taxes | 1,095 | 1,049 |
| Prepaid expenses and other | 2,101 | 1,798 |
| Total current assets | 73,947 | 67,690 |
| Non-current assets: | | |
| Fixed assets, net | 49,916 | 48,556 |
| Drug licenses and related costs, net | 16,260 | 16,026 |
| Restricted cash | 1,000 | 1,000 |
| Deferred taxes | 167 | 240 |
| Other | 922 | 844 |
| Total non-current assets | 68,265 | 66,666 |
| | \$ 142,212 | \$ 134,356 |
| <u>Liabilities and Stockholders Equity</u> | | |
| Current liabilities: | | |
| Accounts payable | \$ 15,724 | \$ 14,566 |
| Accrued expenses | 11,655 | 9,704 |
| Short-term borrowings | | 247 |
| Current portion of long-term debt | | 307 |
| Deferred income | 1,014 | 1,045 |
| Other current liabilities | 1,987 | 1,518 |
| Total current liabilities | 30,380 | 27,387 |
| Non-current liabilities: | | |
| Deferred income | 4,100 | 3,899 |
| Other | 3,677 | 2,739 |
| Total non-current liabilities | 7,777 | 6,638 |

Commitments and contingencies

Stockholders' equity:

| | | |
|---|------------|------------|
| Preferred stock, \$1.00 par value, authorized 2,000 shares, issued and outstanding, none | | |
| Common stock, \$0.02 par value, authorized 100,000 shares, issued and outstanding, 22,271 and 22,262 shares | 445 | 445 |
| Additional paid-in capital | 140,589 | 140,030 |
| Accumulated deficit | (47,061) | (49,016) |
| Accumulated other comprehensive income | 10,082 | 8,872 |
| Total stockholders' equity | 104,055 | 100,331 |
| | \$ 142,212 | \$ 134,356 |

The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of these financial statements.

Table of Contents**Bentley Pharmaceuticals, Inc. and Subsidiaries
Consolidated Income Statements**

| <i>(in thousands, except per share data)</i> | For the Three Months Ended March 31, | |
|--|---|-------------|
| | 2007 | 2006 |
| Revenues: | | |
| Net product sales | \$ 29,114 | \$ 26,570 |
| Licensing and collaboration revenues | 2,277 | 1,708 |
| Total revenues | 31,391 | 28,278 |
| Cost of net product sales | 15,897 | 12,933 |
| Gross profit | 15,494 | 15,345 |
| Operating expenses: | | |
| Selling and marketing | 4,445 | 4,139 |
| General and administrative | 3,646 | 3,904 |
| Research and development | 2,675 | 2,908 |
| Litigation settlement | | 604 |
| Depreciation and amortization | 508 | 436 |
| Total operating expenses | 11,274 | 11,991 |
| Income from operations | 4,220 | 3,354 |
| Other income (expenses): | | |
| Interest income | 182 | 253 |
| Interest expense | (50) | (60) |
| Other, net | 89 | |
| Income before income taxes | 4,441 | 3,547 |
| Provision for income taxes | 2,081 | 2,393 |
| Net income | \$ 2,360 | \$ 1,154 |
| Net income per common share: | | |
| Basic | \$ 0.11 | \$ 0.05 |
| Diluted | \$ 0.10 | \$ 0.05 |

Weighted average common shares outstanding:

| | | |
|-------|--------|--------|
| Basic | 22,293 | 21,954 |
|-------|--------|--------|

| | | |
|---------|--------|--------|
| Diluted | 22,534 | 23,807 |
|---------|--------|--------|

The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of these financial statements.

Table of Contents

Bentley Pharmaceuticals, Inc. and Subsidiaries
Consolidated Statement of Changes in Stockholders' Equity

| <i>(in thousands, except per share data)</i> | \$0.02 Par Value Common Stock | | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive Income | Total |
|--|--|---------------|---|--------------------------------|---|--------------|
| | Shares | Amount | | | | |
| Balance at January 1, 2007 | 22,262 | \$ 445 | \$ 140,030 | \$ (49,016) | \$ 8,872 | \$ 100,331 |
| Cumulative effect change in accounting from the implementation of FIN No. 48 | | | | (405) | | (405) |
| Comprehensive income: | | | | | | |
| Net income | | | | 2,360 | | 2,360 |
| Other comprehensive income: | | | | | | |
| Foreign currency translation adjustment | | | | | 1,210 | 1,210 |
| Comprehensive income | | | | | | \$ 3,570 |
| Stock-based compensation | 9 | | 559 | | | 559 |
| Balance at March 31, 2007 | 22,271 | \$ 445 | \$ 140,589 | \$ (47,061) | \$ 10,082 | \$ 104,055 |

The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of these financial statements.

Table of Contents

Bentley Pharmaceuticals, Inc. and Subsidiaries
Consolidated Statements of Cash Flows

| <i>(in thousands)</i> | For the Three Months Ended March 31, | |
|---|---|-------------|
| | 2007 | 2006 |
| Cash flows from operating activities: | | |
| Net income | \$ 2,360 | \$ 1,154 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 1,548 | 1,280 |
| Non-cash charge for inventory write-down | 302 | |
| Foreign currency gains | (74) | |
| Equity-based compensation expense | 559 | 544 |
| Change in fair value of derivative instrument | 9 | |
| Loss on disposal of assets | 110 | 29 |
| Other non-cash items | 3 | 1 |
| (Increase) decrease in assets and increase (decrease) in liabilities: | | |
| Receivables | (88) | (6,440) |
| Inventories | (447) | (2,378) |
| Deferred income taxes | 46 | (290) |
| Prepaid expenses and other current assets | (288) | 217 |
| Other assets | (24) | (33) |
| Accounts payable and accrued expenses | 2,756 | 6,551 |
| Deferred income | 98 | 979 |
| Other liabilities | 998 | |
| Net cash provided by operating activities | 7,868 | 1,614 |
| Cash flows from investing activities: | | |
| Additions to fixed assets | (1,954) | (3,282) |
| Additions to drug licenses and related costs | (515) | (521) |
| Proceeds from maturity of investments | 2,661 | |
| Net cash provided by (used in) investing activities | 192 | (3,803) |

(Continued on following page)

The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of these financial statements.

Table of Contents

Bentley Pharmaceuticals, Inc. and Subsidiaries
Consolidated Statements of Cash Flows (Concluded)

| | For the Three Months Ended March 31, | |
|---|---|-------------|
| <i>(in thousands)</i> | 2007 | 2006 |
| Cash flows from financing activities: | | |
| Proceeds from the exercise of stock options | \$ | \$ 113 |
| Remittance of employee tax liabilities in exchange for common stock tendered to the Company | | (1,713) |
| Proceeds from borrowings | | 536 |
| Repayment of borrowings | (554) | (789) |
| Net cash used in financing activities | (554) | (1,853) |
| Effect of exchange rate changes on cash | 151 | 174 |
| Net increase (decrease) in cash and cash equivalents | 7,657 | (3,868) |
| Cash and cash equivalents at beginning of period | 12,424 | 32,384 |
| Cash and cash equivalents at end of period | \$ 20,081 | \$ 28,516 |
| Supplemental Disclosures of Cash Flow Information | | |
| The Company paid cash during the period for: | | |
| Interest | \$ | \$ 51 |
| Foreign income taxes | \$ | \$ |
| Supplemental Disclosures of Non-Cash Financing and Investing Activities | | |
| The Company has issued Common Stock as equity-based compensation in lieu of cash during the period as follows: | | |
| Shares | 9 | 4 |
| Amount | \$ 75 | \$ 74 |
| Amounts included in accounts payable and accrued expenses at end of period for fixed asset and drug license purchases | \$ 1,267 | \$ 1,508 |

The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of these financial statements.

Table of Contents

**Bentley Pharmaceuticals, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements**

History and Operations

Bentley Pharmaceuticals, Inc. and Subsidiaries (which may be referred to as Bentley Pharmaceuticals, Bentley, or the Company), headquartered in the U.S., is an international specialty pharmaceutical company, incorporated in the State of Delaware, focused on:

Specialty Generics: development, licensing and sales of generic and branded generic pharmaceutical products and active pharmaceutical ingredients (API) and the manufacturing of pharmaceuticals for others; and

Drug Delivery: research, development and licensing/commercialization of advanced drug delivery technologies and pharmaceutical products.

Bentley's pharmaceutical product sales and licensing activities are based primarily in Spain, where it has a significant commercial presence and manufactures and markets approximately 130 products of various dosages and strengths through three wholly-owned Spanish subsidiaries: Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar. Bentley's products include approximately 180 product presentations (stock keeping units, or SKUs) in four primary therapeutic areas: cardiovascular, gastrointestinal, central nervous system and infectious diseases. Although most of the Company's sales of these products are currently in the Spanish market, it has recently focused on increasing sales in other European countries and other geographic regions through strategic alliances with companies in these territories. The Company continually adds to its product portfolio in response to increasing market demand for generic and branded generic therapeutic agents and, when appropriate, divests portfolio products considered to be redundant or that have become non-strategic. The Company manufactures its finished dosage pharmaceutical products in its Spanish manufacturing facility which received approval from the U.S. Food and Drug Administration (FDA) in late 2006 for the manufacture of Company's first U.S. generic product. The Company owns a manufacturing facility in Spain that specializes in the manufacturing of several API products. This facility has also been approved by the FDA for the manufacture of one ingredient for marketing and sale in the U.S. The Company markets its API products through its Spanish subsidiary, Bentley A.P.I. The Company also has an Irish subsidiary, Bentley Pharmaceuticals Ireland Limited, which launched its first product in late 2006.

The Company has U.S. and international patents and other proprietary rights to technologies that facilitate the absorption of drugs. Bentley is developing products that incorporate its drug delivery technologies and has licensed applications of its proprietary CPE-215[®] drug delivery technology to Auxilium Pharmaceuticals, Inc., which launched Testim[®] in the U.S. market in February 2003. Testim, which incorporates Bentley's CPE-215 drug delivery technology, is a gel indicated for testosterone replacement therapy. Bentley continues to seek other pharmaceutical and biotechnology companies to form additional strategic alliances to facilitate the development and commercialization of other products using its drug delivery technologies, including product candidates that deliver insulin to diabetic patients intranasally, deliver macromolecule therapeutics using a biodegradable Nanocaplet[™] technology and treat nail fungus infections topically.

Basis of Condensed Consolidated Financial Statements

The condensed consolidated financial statements of Bentley as of March 31, 2007 and for the three months ended March 31, 2007 and 2006, included herein, have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted insofar as such information was disclosed in the Company's consolidated financial statements for the year ended December 31, 2006. These condensed consolidated financial statements should be read in conjunction with the summary of

Table of Contents

significant accounting policies and the audited consolidated financial statements and notes thereto included in Bentley's Annual Report on Form 10-K for the year ended December 31, 2006.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements as of March 31, 2007 and for the three months ended March 31, 2007 and 2006 are presented on a basis consistent with the audited consolidated financial statements for the year ended December 31, 2006 and contain all adjustments, consisting only of normal recurring adjustments, necessary to present fairly Bentley's financial position as of March 31, 2007 and the results of its operations and cash flows for the three months ended March 31, 2007 and 2006. The results of operations for the three months ended March 31, 2007 should not necessarily be considered indicative of the results to be expected for the full year ending December 31, 2007.

Cash and cash equivalents

The Company considers all highly liquid investments with remaining maturities of three months or less when purchased to be cash equivalents for purposes of classification in the Consolidated Balance Sheets and the Consolidated Statements of Cash Flows. Investments in securities that do not meet the definition of cash equivalents are classified as *marketable securities* in the Consolidated Balance Sheets.

Included in *cash and cash equivalents* at March 31, 2007 and December 31, 2006 are approximately \$8,896,000 and \$357,000 respectively, of short-term investments considered to be cash equivalents, as the original maturity dates of such investments were three months or less when purchased.

Receivables

Receivables consist of the following (in thousands):

| | March 31, 2007 | December 31, 2006 |
|---|---------------------------|------------------------------|
| Trade receivables (of which \$0 and \$247, respectively, collateralize short-term borrowings with Spanish financial institutions) | \$ 27,698 | \$ 27,880 |
| VAT receivable | 3,977 | 3,151 |
| Royalties receivable | 2,181 | 2,261 |
| Other | 106 | 82 |
| | 33,962 | 33,374 |
| Less-allowance for doubtful accounts | (466) | (411) |
| | \$ 33,496 | \$ 32,963 |

Inventories

Inventories are stated at the lower of cost or market, cost being determined on the first in, first out (FIFO) method. Reserves for slow moving and obsolete inventories are provided based on historical experience and current product demand.

Balances are comprised of the following (in thousands):

| | March 31, 2007 | December 31, 2006 |
|--|---------------------------|------------------------------|
| Raw materials | \$ 9,946 | \$ 8,669 |
| Finished goods | 6,715 | 7,621 |
| | 16,661 | 16,290 |
| Less allowance for slow moving inventory | (11) | (11) |
| | \$ 16,650 | \$ 16,279 |

Table of Contents

The Company's first U.S. generic product was launched in late December 2006. Market price conditions for this product were less favorable than originally estimated. As a result, the Company recorded an adjustment of \$302,000 to *cost of sales* in the three months ended March 31, 2007 to write-down these inventories to their net realizable value.

Included in the Company's inventories at March 31, 2007 and December 31, 2006 are \$816,000 and \$1,338,000 respectively of consigned goods that have been shipped to the Company's collaborator. The Company has received payments of \$878,000 and \$481,000 from its collaborator in anticipation of future sales of these products which have been recorded in *other current liabilities* on the Condensed Consolidated Balance Sheet at March 31, 2007 and December 31, 2006, respectively.

Fixed assets

Fixed assets consist of the following (in thousands):

| | March 31, 2007 | December 31, 2006 |
|-------------------------------|---------------------------|------------------------------|
| Land | \$ 2,905 | \$ 2,875 |
| Buildings and improvements | 23,010 | 17,538 |
| Equipment | 23,291 | 20,591 |
| Furniture and fixtures | 2,033 | 2,138 |
| Other | 343 | 394 |
| | 51,582 | 43,536 |
| Capital in-progress | 14,773 | 20,213 |
| | 66,355 | 63,749 |
| Less accumulated depreciation | (16,439) | (15,193) |
| | \$ 49,916 | \$ 48,556 |

The Company invested approximately \$1,954,000 in capital additions during the three months ended March 31, 2007, primarily for building and improvements. These improvements are expected to increase manufacturing efficiencies and support the Company's future growth.

Depreciation expense of approximately \$91,000 and \$70,000 has been charged to operations as a component of *depreciation and amortization expense* in the Consolidated Income Statements for the three months ended March 31, 2007 and 2006, respectively. Depreciation totaling approximately \$1,040,000 and \$844,000 has been included in *cost of net product sales* during the three months ended March 31, 2007 and 2006, respectively.

Stockholders' equity

A substantial amount of the Company's business is conducted in Europe and is therefore influenced by fluctuations in the U.S. Dollar's value in relation to other currencies, specifically the Euro. The exchange rates at March 31, 2007 and December 31, 2006 are as follows:

| U.S. Dollars per Euro | March 31, 2007 | December 31, 2006 |
|------------------------------------|---------------------------|------------------------------|
| YTD weighted average exchange rate | 1.31 | 1.26 |
| Exchange rate | 1.33 | 1.31 |

The net effect of foreign currency translation on the Company's Condensed Consolidated Financial Statements for the three months ended March 31, 2007 was a net increase of \$1,210,000 and the cumulative historical effect as of March 31, 2007 totaled \$10,082,000, as reflected in the Consolidated Balance Sheets as *accumulated other comprehensive income*. The carrying value of assets and liabilities can be materially affected by foreign currency translation, as can the translated amounts of revenues and expenses. Nonetheless, management does not plan to modify its business practices.

Table of Contents**Supplemental disclosures related to Consolidated Statements of Cash Flows**

During the three months ended March 31, 2006, the Chief Executive Officer (CEO) and the Chief Medical Officer (CMO) of the Company exercised stock options to purchase an aggregate of 533,300 shares of the Company's Common Stock. In satisfaction of the option exercise prices, the Company received an aggregate of approximately 177,800 shares of previously acquired Bentley Common Stock, with a fair market value of approximately \$2,347,500. The Company also received a total of approximately 129,600 shares of Common Stock, with a fair market value of approximately \$1,712,800, from these employees in order to satisfy minimum federal and statutory tax withholding requirements. The shares of Common Stock acquired by the Company in connection with these stock option exercises were recorded at fair market value and are held by the Company as treasury shares. As of March 31, 2007 and December 31, 2006, the Company has recorded approximately 849,100 shares, as treasury stock, with an historical cost of \$10,781,700, which has been accounted for as a reduction of *common stock* and *additional paid in capital*.

Revenue recognition

Revenue on product sales is recognized when persuasive evidence of an arrangement exists, the price is fixed and final, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. The Company generally obtains purchase authorizations from its customers for a specified amount of product at a specified price and considers delivery to have occurred when the customer takes possession of the product. The Company provides its customers with a limited right of return. Revenue is recognized upon delivery and a reserve for sales returns is recorded when considered appropriate. The Company has demonstrated the ability to make reasonable and reliable estimates of product returns in accordance with Statement of Financial Accounting Standards (SFAS) No. 48, *Revenue Recognition When Right of Return Exists*, and of allowances for doubtful accounts based on significant historical experience.

Revenue from service, research and development, and licensing agreements is recognized when the service procedures have been completed or as revenue recognition criteria have been met for each separate unit of accounting as defined in Emerging Issues Task Force (EITF) Issue No. 00-21, *Accounting for Revenue Arrangements with Multiple Deliverables*. The Company has deferred the recognition of approximately \$4,479,000 and \$4,797,000 of licensing revenues as of March 31, 2007 and December 31, 2006, respectively, for which the earnings process has not been completed.

The Company earns royalty revenues on Auxilium's sales of Testim, which incorporates the Company's CPE-215 permeation enhancement technology. Since 2003, Auxilium has sold Testim to pharmaceutical wholesalers and chain drug stores, which have the right to return purchased product prior to the units being dispensed through patient prescriptions. Historically, customer returns were not able to be reasonably estimated. Therefore, in accordance with SFAS No. 48, the Company deferred the recognition of royalty revenues on product shipments of Testim until the units were dispensed through patient prescriptions. In June 2006, the Company determined that it could reasonably estimate future product returns on sales of Testim based on historical return experience. As a result the Company recorded a change in estimate and recognized its deferred Testim royalties. Therefore, there were no deferred Testim royalties as of March 31, 2007. However, deferred income from Testim royalties totaled \$372,000 as of March 31, 2006. The Company recognized royalty revenues of \$2,157,000 and \$1,628,000 in the three months ended March 31, 2007 and 2006, respectively.

Provision for income taxes

The Company adopted the provisions of Financial Standards Accounting Board Interpretation No. 48, *Accounting for Uncertainty in Income Taxes* (FIN No. 48) an interpretation of FASB Statement No. 109, *Accounting for Income Taxes*, (SFAS No. 109) on January 1, 2007. The purpose of FIN No. 48 is to clarify and set forth consistent rules for accounting for uncertain tax positions in accordance with SFAS No. 109 by requiring the application of a more likely than not threshold for the recognition and derecognition of tax positions. As a result of the implementation of FIN No. 48, the Company recorded a \$405,000 increase in its non-current liabilities for uncertain tax positions which was accounted for as a reduction to the January 1, 2007 balance of retained earnings. In order to conform with the balance sheet disclosure requirements of FIN No. 48, the Company also reclassified its previously recorded liabilities of \$546,000 for uncertain tax positions from accrued expenses to other non-current liabilities at March 31, 2007. The Company had \$935,000 of unrecognized tax benefits at the

Table of Contents

adoption date, all of which would affect its effective tax rate if recognized. The Company had \$957,000 of unrecognized tax benefits at March 31, 2007. The Company recognizes interest and penalties related to uncertain tax positions as a component of the provision for income taxes. As of the date of adoption, the Company had approximately \$249,000 of accrued penalties and \$51,000 of accrued interest related to its uncertain tax positions.

Tax years ranging from 2002 to 2006 remain open to examination by the major taxing authorities in jurisdictions where the Company is subject to taxation.

As a result of reporting taxable income in Spain, the Company recorded provisions for foreign income taxes totaling \$2,081,000 and \$2,393,000 for the three months ended March 31, 2007 and 2006, respectively. The provisions represented 32% and 35% of the pre-tax income reported in Spain of \$6,468,000 and \$6,898,000 for the three months ended March 31, 2007 and 2006, respectively. The provisions represented 47% and 67% of consolidated pre-tax income for the three months ended March 31, 2007 and 2006, respectively.

The Company maintains various agreements by and between Bentley Pharmaceuticals, Inc. and its subsidiaries. Income and expenses resulting from these agreements are eliminated in consolidation; however, the related transactions affect the Company's consolidated income tax provision. See further information regarding the Company's consolidated tax provision by tax jurisdiction in the Results of Operations section of Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations.

As future operating profits in the U.S. and Ireland cannot be reasonably assured, no tax benefit has been recorded for the related losses, which totaled approximately \$2,025,000 and \$3,351,000 for the three months ended March 31, 2007 and 2006, respectively. Accordingly, the Company has established valuation allowances equal to the full amount of the U.S. and Irish deferred tax assets. Should the Company determine that it is more likely than not that it will realize certain of its net deferred tax assets for which it has previously provided a valuation allowance, an adjustment would be required to reduce the existing valuation allowance.

Basic and diluted net income per common share

Basic net income per common share is based on the weighted average number of shares of common stock outstanding during each period. The Company included the dilutive effect of outstanding stock options, as calculated using the treasury stock method, when determining the diluted net income per common share for the three months ended March 31, 2007 and 2006.

The following is a reconciliation between basic and diluted net income per common share for the three months ended March 31, 2007 and 2006. Dilutive securities issuable for the three months ended March 31, 2007 and 2006 include approximately 241,000 and 1,853,000 dilutive incremental shares, respectively issuable as a result of various stock options that are outstanding.

For the Three Months Ended March 31, 2007 (in thousands, except per share data):

| | Basic EPS | Effect of Dilutive Securities | Diluted EPS |
|--|------------------|--|------------------------|
| Net Income | \$ 2,360 | \$ | \$ 2,360 |
| Weighted Average Common Shares Outstanding | 22,293 | 241 | 22,534 |
| Net Income Per Common Share | \$ 0.11 | \$ | \$ 0.10 |

Table of Contents

For the Three Months Ended March 31, 2006 (in thousands, except per share data):

| | Basic EPS | Effect of Dilutive Securities | Diluted EPS |
|--|------------------|--------------------------------------|--------------------|
| Net Income | \$ 1,154 | \$ | \$ 1,154 |
| Weighted Average Common Shares Outstanding | 21,954 | 1,853 | 23,807 |
| Net Income Per Common Share | \$ 0.05 | \$ | \$ 0.05 |

For the three months ended March 31, 2007, options to purchase 2,434,000 shares of Common Stock were excluded from the diluted EPS presentation as determined under the treasury stock method, because their exercises prices were greater than the average market value of the Common Stock during the three months ended March 31, 2007. All of the Company's 3,369,000 outstanding stock options in the quarter ended March 31, 2006 were included in the diluted EPS presentation, as their exercise prices were less than the average fair value of the Common Stock for the three months ended March 31, 2006.

Share-based compensation

The Company has in effect equity incentive plans (the Plans), pursuant to which directors, officers, employees and consultants of the Company have been awarded grants of restricted stock units and options to purchase the Company's Common Stock. As of March 31, 2007, approximately 4,482,000 shares of Common Stock have been reserved for issuance under the Plans. Approximately 3,745,000 of the shares are outstanding, excluding 30,000 shares underlying restricted stock units, contingently issuable to non-employee directors pursuant to the terms and conditions of the respective restricted stock unit agreements. The balance of approximately 737,000 shares is available for future issuance. Of the shares available for future issuance, approximately 290,000 are available for future stock options only and the remainder are available for any type of award allowed under the plan.

While there were no option exercises in the three months ended March 31, 2007, approximately 10,000 restricted stock units vested during the period. The underlying shares of the vested units are contingently issuable to non-employee directors pursuant to the terms and conditions of the respective restricted stock unit agreements.

Share-based compensation expense recorded for stock option and restricted stock unit awards to employees and non-employee directors for the three months ended March 31, 2007 and 2006 was approximately \$497,000 and \$463,000, respectively. The related expenses were recorded in the Company's Condensed Consolidated Income Statements as follows (in thousands):

| | For the Three Months Ended March 31, | |
|--|---|-------------|
| | 2007 | 2006 |
| <i>Cost of net product sales</i> | \$ 8 | \$ 10 |
| <i>Selling and marketing expenses</i> | 5 | 5 |
| <i>General and administrative expenses</i> | 310 | 304 |
| <i>Research and development expenses</i> | 174 | 144 |
| | \$ 497 | \$ 463 |

No related compensation expense was capitalized as the cost of an asset and there was no impact on net cash provided by operating activities or net cash used in financing activities as a result of these share-based transactions.

The Company issued 8,590 and 4,255 shares in the three months ended March 31, 2007 and 2006 as matching contributions for the Company's 401(k) Plan. *General and administrative expenses* include approximately \$31,300 and \$34,000 of such non-cash share-based compensation for the three months ended March 31, 2007 and 2006, respectively. *Research and development expenses* include approximately \$43,500 and \$47,000 of such non-cash share-based compensation for the three months ended March 31, 2007 and 2006, respectively.

Table of Contents**Business segment information**

SFAS No. 131, *Disclosures About Segments of an Enterprise and Related Information*, defines how operating segments are determined and requires disclosure of certain financial and descriptive information about a company's operating segments. The Company, headquartered in the U.S., is an international specialty pharmaceutical company which operates in two business segments, specialty generics and drug delivery, and two geographical locations (Europe and the U.S.).

The Company's specialty generics segment is based in Europe and develops and manufactures a growing portfolio of generic and branded generic pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and central nervous system diseases through its subsidiary, Laboratorios Belmac, and markets these pharmaceutical products through its subsidiaries, Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland. The U.S. operations of this segment include any sales of generic pharmaceuticals in the U.S. and continued research and development activities to bring additional generic pharmaceutical products into the U.S. This segment also manufactures and sells active pharmaceutical ingredients through its subsidiary, Bentley A.P.I.

The Company's drug delivery segment is based in both the U.S. and Europe and is focused on the advancement of proprietary drug delivery technologies that enhance or facilitate the absorption of pharmaceutical compounds across various membranes. In the U.S., the Company's activities consist primarily of licensing, product research and development, business development activities, corporate management and administration.

Set forth in the tables below is certain financial information with respect to the Company's business and geographical segments for the three months ended March 31, 2007 and 2006. These segments use the same accounting policies as those described in the summary of significant accounting policies in Note 2 of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 (the 2006 Form 10-K).

As of and for the Three Months Ended March 31, 2007 (in thousands):

| | Specialty Generics | | Drug Delivery | | Consolidated |
|---------------------------------------|--------------------|--------|---------------|-------|--------------|
| | Europe | U.S. | Europe | U.S. | |
| Net product sales | \$28,906 | \$ 208 | \$ | \$ | \$29,114 |
| Licensing and collaboration revenues | 114 | | | 2,163 | 2,277 |
| Total revenues | 29,020 | 208 | | 2,163 | 31,391 |
| Cost of net product sales | 15,396 | 501 | | | 15,897 |
| Gross profit | 13,624 | (293) | | 2,163 | 15,494 |
| Selling and marketing expense | 4,445 | | | | 4,445 |
| General and administrative expense | 2,275 | | | 1,371 | 3,646 |
| Research and development expense | 481 | | 1,097 | 1,097 | 2,675 |
| Depreciation and amortization expense | 274 | 39 | | 195 | 508 |
| Litigation settlement | | | | | |
| Income from operations | 6,149 | (332) | (1,097) | (500) | 4,220 |
| Interest income | 65 | | | 117 | 182 |
| Interest expense | (45) | | | (5) | (50) |
| Other income (expense), net | 92 | | | (3) | 89 |
| Income before income taxes | 6,261 | (332) | (1,097) | (391) | 4,441 |
| Provision for income taxes | 2,081 | | | | 2,081 |
| Net income (loss) | 4,180 | (332) | (1,097) | (391) | 2,360 |
| Expenditures for fixed assets | 1,934 | | | 20 | 1,954 |
| Expenditures for drug licenses | 336 | 32 | | 147 | 515 |

Table of Contents

As of and for the Three Months Ended March 31, 2006 (in thousands):

| | Specialty Generics | | Drug Delivery | | Consolidated |
|---------------------------------------|--------------------|-------|---------------|---------|--------------|
| | Europe | U.S. | Europe | U.S. | |
| Net product sales | \$26,570 | \$ | \$ | \$ | \$26,570 |
| Licensing and collaboration revenues | 73 | | | 1,635 | 1,708 |
| Total revenues | 26,643 | | | 1,635 | 28,278 |
| Cost of net product sales | 12,933 | | | | 12,933 |
| Gross profit | 13,710 | | | 1,635 | 15,345 |
| Selling and marketing expense | 4,139 | | | | 4,139 |
| General and administrative expense | 1,850 | | 49 | 2,005 | 3,904 |
| Research and development expense | 494 | | 1,207 | 1,207 | 2,908 |
| Depreciation and amortization expense | 254 | 21 | | 161 | 436 |
| Litigation settlement | 88 | 516 | | | 604 |
| Income from operations | 6,885 | (537) | (1,256) | (1,738) | 3,354 |
| Interest income | 46 | | | 207 | 253 |
| Interest expense | (60) | | | | (60) |
| Other income (expense), net | | | | | |
| Income before income taxes | 6,871 | (537) | (1,256) | (1,531) | 3,547 |
| Provision for income taxes | 2,393 | | | | 2,393 |
| Net income (loss) | 4,478 | (537) | (1,256) | (1,531) | 1,154 |
| Expenditures for fixed assets | 3,200 | | | 82 | 3,282 |
| Expenditures for drug licenses | 346 | 5 | | 170 | 521 |

As of March 31, 2007 (in thousands):

| | Specialty Generics | | Drug Delivery | | Consolidated |
|---------------------------------|--------------------|-------|---------------|----------|--------------|
| | Europe | U.S. | Europe | U.S. | |
| Receivables, net | \$ 31,192 | \$ | \$ | \$ 2,304 | \$ 33,496 |
| Other current assets | 28,680 | 874 | | 10,897 | 40,451 |
| Fixed assets | 47,138 | | | 2,778 | 49,916 |
| Drug licenses and related costs | 10,925 | 1,827 | | 3,508 | 16,260 |
| Other non-current assets | 893 | | | 1,196 | 2,089 |
| Total assets | 118,828 | 2,701 | | 20,683 | 142,212 |
| Current liabilities | 27,061 | 918 | | 2,401 | 30,380 |
| Non-current liabilities | 7,777 | | | | 7,777 |
| Total liabilities | 34,838 | 918 | | 2,401 | 38,157 |

As of December 31, 2006 (in thousands):

| | Specialty Generics | | Drug Delivery | | Consolidated |
|---------------------------------|--------------------|-------|---------------|----------|--------------|
| | Europe | U.S. | Europe | U.S. | |
| Receivables, net | \$ 30,558 | \$ 39 | \$ | \$ 2,366 | \$ 32,963 |
| Other current assets | 21,758 | 1,338 | | 11,631 | 34,727 |
| Fixed assets | 45,738 | | | 2,818 | 48,556 |
| Drug licenses and related costs | 10,697 | 1,833 | | 3,496 | 16,026 |
| Other non-current assets | 885 | | | 1,199 | 2,084 |
| Total assets | 109,636 | 3,210 | | 21,510 | 134,356 |
| Current liabilities | 24,651 | | | 2,736 | 27,387 |

Edgar Filing: BENTLEY PHARMACEUTICALS INC - Form 10-Q

| | | | |
|-------------------------|--------|-------|--------|
| Non-current liabilities | 6,638 | | 6,638 |
| Total liabilities | 31,289 | 2,736 | 34,025 |

15

Table of Contents

Recently issued accounting pronouncements

On January 1, 2007, the Company adopted SFAS No. 157, *Fair Value Measurements* (SFAS No. 157), which provides guidance for measuring the fair value of assets and liabilities, as well as requires expanded disclosures about fair value measurements. SFAS No. 157 indicates that fair value should be determined based on the assumptions marketplace participants would use in pricing the asset or liability, and provides additional guidelines to consider in determining the market-based measurement. The adoption of SFAS No. 157 did not have an impact on the Company's consolidated financial statements.

In February 2007, the Financial Accounting Standards Board (FASB) issued SFAS No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities, including an amendment of FASB Statement No. 115*, (SFAS No. 159). SFAS No. 159 permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. SFAS No. 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. SFAS No. 159 becomes effective for the Company as of January 1, 2008. The Company is currently evaluating the impact of SFAS No. 159 on the Company's financial statements.

Reclassifications

Certain costs incurred in *general and administrative expenses* in prior periods associated with a litigation settlement in December of 2006 have been reclassified from *general and administrative expenses* to *litigation settlement* to conform with the Company's current presentation.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis together with all financial and non-financial information appearing elsewhere in this report and with our consolidated financial statements and related notes included in our 2006 Annual Report on Form 10-K, which has been previously filed with the SEC. In addition to historical information, the following discussion and other parts of this report contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to competitive factors and other risks discussed in our 2006 Annual Report on Form 10-K under Item 1A, Risk Factors .

Overview

We are a specialty pharmaceutical company focused on:

Specialty Generics: development, licensing and sales of generic and branded generic pharmaceutical products and active pharmaceutical ingredients and the manufacturing of pharmaceuticals for ourselves and others in Spain, other parts of Europe and international markets, including the U.S. market; and

Drug Delivery: research, development and licensing/commercialization of advanced proprietary drug delivery technologies for new and existing pharmaceutical products.

Generic Pharmaceuticals

Our pharmaceutical product sales activities are based in Spain, where we have a significant commercial presence and we manufacture and market approximately 130 pharmaceutical products of various dosages and strengths. These products include approximately 180 product presentations or SKUs, in four primary therapeutic areas: cardiovascular, gastrointestinal, central nervous system and infectious diseases. Revenues derived from our top three product lines, represented approximately 26% of our net product revenues in the three months ended March 31, 2007. We market our branded generic and generic products to physicians, pharmacists and hospitals through our three separate sales and marketing organizations based in Spain: Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar. In past years we expanded our geographic sales to countries outside of Spain including the U.S. and several countries in E.U. As of March 31, 2007 approximately 26% of our net product sales were derived from sales outside of Spain. Our generic simvastatin product, which is manufactured at our FDA approved finish dosage facility in Spain, was launched in the U.S. in December of 2006. The launch of our first U.S. generic product marked a significant strategic milestone for us; however, market price conditions for our generic simvastatin have been determined to be less favorable than our initial projections. As a result, we have recorded an inventory write-down of approximately \$302,000 in the three months ended March 31, 2007.

While the pricing of our pharmaceutical products is influenced by market forces (size of the market, number of competitors, etc.) our pricing is also subject to governmental price controls in Spain and other countries. The majority of our products are subject to price controls set in place by the Spanish government. The Spanish government enacted legislation effective March 1, 2007 which reduced the amount it will reimburse for pharmaceutical products. As a result of the legislation our sales force began marketing our products at lower selling prices in Spain as early as February 2007. We experienced reduced sales levels in the beginning of the first quarter of 2007 as Spanish wholesalers and pharmacies minimized order quantities until they were able to purchase our products at the new lower prices. Once we began selling at the new prices we experienced an increase in the number of our units sold. While the increased unit volume has offset the impact of the reduced selling prices on our net product sales, our gross margins have decreased from 51% in the three months ended March 31, 2006 to 45% in the three months ended March 31, 2007 (excluding the \$302,000 inventory write-down associated with our U.S. generic simvastatin discussed above). We have implemented strategies to mitigate lower selling prices which include strategies to reduce manufacturing costs

Table of Contents

and increase sales volumes. We are seeking to continue expanding our product sales in other geographic regions, including the U.S., through strategic alliances. We are targeting markets that offer compatible regulatory approval regimes and attractive product margins. In addition, we expect to grow our business by developing and acquiring rights to market additional products to sell through our organization and our strategic alliances. We continually acquire rights to new products in response to increasing market demand for generic and branded generic therapeutic products.

We also manufacture and market active pharmaceutical ingredients, or API, through our subsidiary, Bentley A.P.I. Our API facility has been approved by the FDA for the manufacture of one ingredient for marketing and sale in the U.S. In addition, our Spanish pharmaceutical product manufacturing facility produces pharmaceutical products that are marketed by other pharmaceutical companies both in Spain and in other international markets, including the U.S.

Drug Delivery Technologies and Products

We develop and co-develop products that incorporate our drug delivery technologies. We have licensed applications of our proprietary CPE-215 drug delivery technology to Auxilium Pharmaceuticals, Inc., which launched Testim the first product incorporating our CPE-215 drug delivery technology, in the United States in February 2003. Testim is a gel indicated for testosterone replacement therapy. Testim is also approved for marketing in 15 European countries and Canada. We are in discussions with other pharmaceutical and biotechnology companies to form additional strategic alliances to facilitate the development and commercialization of other products using our drug delivery technologies, including product candidates that deliver insulin to diabetic patients intranasally, deliver macromolecule therapeutics using a biodegradable Nanocaplet™ technology and treat nail fungus infections topically.

Research and Development Focus

Our U.S. research and development activities are primarily focused on the development of Nasulin™, our intranasal insulin product candidate. In 2004 we concluded a Phase IIA study for Nasulin in Type I diabetic patients using our CPE-215 technology. The full results of that trial were published in 2006 in the journal *Diabetes Technology & Therapeutics*, Volume 8, Number 1. In 2006, we completed an additional Phase I study in Ireland and advanced our Phase IIA studies in the U.S. In first quarter of 2007 we completed preparations for a Phase II study in India which we expect to begin in the second quarter of 2007. Portions of the results from our U.S. and Irish studies will be made available at the American Diabetes Association 67th Sessions in Chicago, IL in June 2007. We expect the U.S. development and clinical programs for Nasulin to continue and expand both outside and inside the U.S. We are also continuing our clinical programs to support our strategy for the distribution of our generic pharmaceutical products in other countries, including the U.S. We expect to continue to invest our resources to conduct clinical trials and support the required regulatory submissions for our clinical programs. As a result, we expect to incur increased costs for product formulation and testing efforts.

Effect of Foreign Currency Fluctuations

A substantial amount of our business is conducted in Europe and, therefore our results, which are measured in U.S. Dollars, are influenced by fluctuations in the U.S. Dollar's value in relation to other currencies, specifically the Euro. An increase in the weighted average value of the Euro in relation to the U.S. Dollar over the prior year first quarter, had the following impact on the results of our operations when reported in U.S. Dollars: (1) total revenues were increased by approximately \$2,419,000, (2) gross profit was increased by approximately \$1,138,000, (3) operating expenses and other income (expense) increased by approximately \$697,000, (4) provision for income taxes was increased by approximately \$172,000, which resulted in (5) an increase to net income of approximately \$269,000.

Table of Contents

This section includes constant currency measures. Constant currency removes from financial data the impact of changes in exchange rates between the U.S. Dollar and other currencies, particularly the Euro, by translating current period financial data into U.S. Dollars using the same foreign currency exchange rates that were used to translate the financial data for the previous period. We believe presenting certain results on a constant currency basis is useful to investors because it allows a more meaningful comparison of the performance of our European operations from period to period.

RESULTS OF OPERATIONS:**Three Months Ended March 31, 2007 versus Three Months Ended March 31, 2006***Revenues*

| <i>(in thousands)</i> | <i>For the Three Months Ended March 31,</i> | | | | <i>Change</i> | |
|---|---|----------|-------------|----------|---------------|----------|
| | <i>2007</i> | <i>%</i> | <i>2006</i> | <i>%</i> | <i>\$</i> | <i>%</i> |
| <i>Specialty Generics</i> | | | | | | |
| <i>Net product sales</i> | \$29,114 | 93% | \$26,570 | 94% | \$2,544 | 10% |
| <i>Licensing and collaboration revenues</i> | 114 | * | 73 | * | 41 | 56% |
| | 29,228 | 93% | 26,643 | 94% | 2,585 | 10% |
| <i>Drug Delivery Licensing and collaboration revenues</i> | | | | | | |
| <i>Licensing and collaboration revenues</i> | 2,163 | 7% | 1,635 | 6% | 528 | 32% |
| <i>Total revenues</i> | \$31,391 | 100% | \$28,278 | 100% | \$3,113 | 11% |

* *Less than 1%*

Total revenues for the three months ended March 31, 2007 increased \$3,113,000 from the same period in the prior year. Our specialty generics business experienced increased demand when compared to the comparable quarter of 2006. However, price reductions in Spain have resulted in net product sales that are consistent with the comparable period of 2006 when expressed in constant currency. Our drug delivery revenues increased 32% from the first quarter of 2007 due to increased royalties earned on sales of Testim. Based on industry sources, Testim was reported to capture approximately 19% of all testosterone gel replacement prescriptions in the U.S. market as of March 31, 2007, compared to approximately 17% of all testosterone gel replacement prescriptions as of March 31, 2006.

Our revenues are generated through our primary sales channels of branded generic pharmaceuticals, generic pharmaceuticals, sales to licensees and others, as well as licensing and collaboration arrangements. The following is a summary of our revenues by sales channel and top-selling product lines:

For the three months ended March 31, 2007:

| <i>(in thousands)</i> | <i>Revenues Within Spain</i> | | | <i>Revenues Outside of Spain</i> | <i>Total</i> | <i>% of Total Revenues</i> |
|-----------------------|------------------------------|-----------------|--------------|----------------------------------|--------------|----------------------------|
| | <i>Branded Generics</i> | <i>Generics</i> | <i>Other</i> | | | |
| <i>Omeprazole</i> | \$ 551 | \$ 3,870 | \$ | \$ | \$ 4,421 | 14% |
| <i>Simvastatin</i> | 366 | 1,339 | | | 1,705 | 6% |
| <i>Enalapril</i> | 1,314 | 391 | | | 1,705 | 6% |
| <i>Paroxetine</i> | 449 | 897 | | | 1,346 | 4% |
| <i>Codeisan</i> | 1,270 | | | | 1,270 | 4% |

Edgar Filing: BENTLEY PHARMACEUTICALS INC - Form 10-Q

| | | | | | | |
|--------------------------------------|---------|----------|---------|---------|----------|------|
| <i>All other products</i> | 3,046 | 4,182 | 275 | 957 | 8,460 | 27% |
| <i>Sales to licensees and others</i> | | | 3,670 | 6,537 | 10,207 | 32% |
| <i>Licensing and collaborations</i> | | | 114 | 2,163 | 2,277 | 7% |
| <i>Total Revenues</i> | \$6,996 | \$10,679 | \$4,059 | \$9,657 | \$31,391 | 100% |
| <i>% of Q-1 2007 Revenues</i> | 22% | 34% | 13% | 31% | 100% | |

19

Table of Contents

For the three months ended March 31, 2006:

| <i>(in thousands)</i> | <i>Revenues Within Spain</i> | | | <i>Revenues</i> | | <i>% of Total Revenues</i> |
|--------------------------------------|------------------------------|-----------------|--------------|-------------------------|--------------|----------------------------|
| | <i>Branded Generics</i> | <i>Generics</i> | <i>Other</i> | <i>Outside of Spain</i> | <i>Total</i> | |
| <i>Omeprazole</i> | \$ 629 | \$ 4,383 | \$ | \$ | \$ 5,012 | 18% |
| <i>Simvastatin</i> | 444 | 1,471 | | | 1,915 | 7% |
| <i>Enalapril</i> | 918 | 723 | | | 1,641 | 6% |
| <i>Paroxetine</i> | 377 | 816 | | | 1,193 | 4% |
| <i>Codeisan</i> | 852 | | | | 852 | 3% |
| <i>All other products</i> | 2,615 | 3,224 | 310 | 357 | 6,506 | 23% |
| <i>Sales to licensees and others</i> | | | 2,626 | 6,825 | 9,451 | 33% |
| <i>Licensing and collaborations</i> | | | 73 | 1,635 | 1,708 | 6% |
| <i>Total Revenues</i> | \$5,835 | \$10,617 | \$3,009 | \$8,817 | \$28,278 | 100% |
| <i>% of Q-1 2006 Revenues</i> | 21% | 37% | 11% | 31% | 100% | |

Branded Generic Pharmaceutical Products

| <i>(in thousands)</i> | <i>For the Three Months Ended March 31,</i> | | | | <i>Change</i> | |
|---|---|----------|-------------|----------|---------------|----------|
| | <i>2007</i> | <i>%</i> | <i>2006</i> | <i>%</i> | <i>\$</i> | <i>%</i> |
| <i>Branded Generic Product Sales:</i> | | | | | | |
| <i>Enalapril</i> | \$ 1,314 | 19% | \$ 918 | 16% | \$ 396 | 43% |
| <i>Codeisan</i> | 1,270 | 18% | 852 | 15% | 418 | 49% |
| <i>Lansoprazole</i> | 856 | 12% | 660 | 11% | 196 | 30% |
| <i>Omeprazole</i> | 551 | 8% | 629 | 11% | (78) | -12% |
| <i>Ibuprofen</i> | 483 | 7% | 376 | 6% | 107 | 28% |
| <i>All other branded generic products</i> | 2,522 | 36% | 2,400 | 41% | 122 | 5% |
| <i>Total branded generic sales</i> | \$ 6,996 | 100% | \$ 5,835 | 100% | \$ 1,161 | 20% |

Sales of our branded generic pharmaceutical products increased by 10% in constant currency when compared to the three months ended March 31, 2006 despite the recent price reductions in Spain. Increased unit volume in the first quarter of 2007, primarily from sales of Codeisan and enalapril, offset the effect of the price reductions on our branded generic sales. Sales of enalapril during the quarter accounted for 34% of the increase in our branded generic sales. We also experienced a 49% increase in sales of Codeisan, our leading cough product, as a result of a more severe cold, cough and flu season. While we expect to continue to develop, acquire, launch and support new and existing branded generic products, our growth strategy is focused on sales of generic products and sales outside of Spain.

Generic Pharmaceutical Products

| <i>(in thousands)</i> | <i>For the Three Months Ended March 31,</i> | | <i>Change</i> |
|-----------------------|---|--|---------------|
|-----------------------|---|--|---------------|

Edgar Filing: BENTLEY PHARMACEUTICALS INC - Form 10-Q

| | 2007 | % | 2006 | % | \$ | % |
|-----------------------------------|-----------|------|-----------|------|----------|------|
| <i>Generic Product Sales:</i> | | | | | | |
| <i>Omeprazole</i> | \$ 3,870 | 36% | \$ 4,383 | 41% | \$ (513) | -12% |
| <i>Simvastatin</i> | 1,339 | 13% | 1,471 | 14% | (132) | -9% |
| <i>Paroxetine</i> | 897 | 8% | 816 | 8% | 81 | 10% |
| <i>Trimetazidine</i> | 729 | 7% | 549 | 5% | 180 | 33% |
| <i>Pentoxifylline</i> | 704 | 7% | 603 | 6% | 101 | 17% |
| <i>All other generic products</i> | 3,140 | 29% | 2,795 | 26% | 345 | 12% |
| <i>Total generic sales</i> | \$ 10,679 | 100% | \$ 10,617 | 100% | \$ 62 | 1% |

Sales of our generic pharmaceutical products decreased by 8% in constant currency when compared to the three months ended March 31, 2006 as a result of the recent price reductions in Spain. While we also experienced an increased unit volume in our generic sales, primarily from sales of omeprazole and simvastatin, the increase was not enough to offset the effect of the price reductions. We

Table of Contents

expect to continue to increase our generic drug portfolio and increase our generic drug sales in Spain as products patent protection rights expire in the future.

Sales to Licensees and Others

| <i>(in thousands)</i> | <i>For the Three Months Ended</i> | | <i>Change</i> | |
|---------------------------|-----------------------------------|-----------------|---------------|-----------|
| | <i>2007</i> | <i>2006</i> | <i>\$</i> | <i>%</i> |
| <i>Specialty generics</i> | <i>\$ 10,207</i> | <i>\$ 9,451</i> | <i>\$756</i> | <i>8%</i> |

In addition to manufacturing and selling our own branded generic and generic products, we license the right to market products to others within and outside of Spain. These license agreements are usually accompanied by long-term exclusive supply agreements, whereby our licensees purchase the licensed products from our manufacturing facility (and are recorded as *net product sales* in the Condensed Consolidated Income Statements). As of March 31, 2007, our Spanish operations have executed 209 license agreements for product registrations, of which 20 with customers in Spain and 95 with customers outside of Spain, cover actively marketed products that are generating revenues. The remaining licenses (10 with customers in Spain, 11 with customers in Ireland and 73 with customers outside of Spain and Ireland) are for products that are awaiting regulatory approvals. Additionally, we have 16 contract manufacturing agreements in effect in Spain and 6 contract manufacturing agreements in effect in other countries. Our clients market these products under their own names and with their own labeling. Many of the products we manufacture for others use the same active ingredients that are used in our own marketed products. Sales to licensees and others in the three months ended March 31, 2007 increased \$756,000 when compared to the first quarter of 2006; however, sales to licenses and others decreased by 1% in constant currency. Sales to our licensees and contract manufacturing customers are usually of larger quantities and occur on a less frequent basis than our normal sales in Spain. Therefore, the shipment of one order, or delayed shipment of one order, could cause significant fluctuations from quarter to quarter.

Licensing and Collaboration Revenues

| <i>(in thousands)</i> | <i>For the Three Months Ended</i> | | <i>Change</i> | |
|---------------------------|-----------------------------------|-----------------|---------------|------------|
| | <i>2007</i> | <i>2006</i> | <i>\$</i> | <i>%</i> |
| <i>Specialty generics</i> | <i>\$ 114</i> | <i>\$ 73</i> | <i>\$ 41</i> | <i>56%</i> |
| <i>Drug delivery</i> | <i>2,163</i> | <i>1,635</i> | <i>528</i> | <i>32%</i> |
| <i>Total</i> | <i>\$ 2,277</i> | <i>\$ 1,708</i> | <i>\$ 569</i> | <i>33%</i> |

Licensing and collaboration revenues increased by 33% and accounted for 7% of total revenues for the three months ended March 31, 2007 compared to 6% for the three months ended March 31, 2006. Our licensing and collaboration revenues are primarily royalties earned from sales of Testim. These royalties totaled \$2,157,000 in the first quarter of 2007 compared to \$1,628,000 in the first quarter of 2006.

Gross Profit

| <i>(in thousands)</i> | <i>For the Three Months Ended</i> | | <i>Change</i> | |
|---------------------------|-----------------------------------|------------------|-----------------|------------|
| | <i>2007</i> | <i>2006</i> | <i>\$</i> | <i>%</i> |
| <i>Specialty generics</i> | <i>\$ 13,331</i> | <i>\$ 13,710</i> | <i>\$ (379)</i> | <i>-3%</i> |
| <i>Drug delivery</i> | <i>2,163</i> | <i>1,635</i> | <i>528</i> | <i>32%</i> |
| <i>Total</i> | <i>\$ 15,494</i> | <i>\$ 15,345</i> | <i>\$ 149</i> | <i>1%</i> |

Gross profit increased by approximately \$149,000, or 1% when compared to the three months ended March 31, 2006, primarily from increased Testim royalties reported by our drug delivery business. Despite an increase in unit volume, gross profit reported by our specialty generics business decreased by 3% when compared to the same quarter of the prior year. We estimate that the price reductions in Spain reduced our gross margin on net product sales by 4% in the first quarter of 2007. Gross profit related to our specialty

Table of Contents

generics business also includes a \$302,000 adjustment to write-down our U.S. generic inventory to its net realizable value in the three months ended March 31, 2007. Excluding the inventory write-down, our gross margins on net product sales decreased from 51% to 46% in the three months ended March 31, 2006 and 2007, respectively. We expect our margins to gradually improve over time as we continue to implement our strategies to mitigate the impact of the price reductions.

Selling and Marketing Expenses

| <i>(in thousands)</i> | <i>For the Three Months Ended</i> | | <i>Change</i> | |
|---------------------------|-----------------------------------|-------------|---------------|----------|
| | <i>2007</i> | <i>2006</i> | <i>\$</i> | <i>%</i> |
| <i>Specialty generics</i> | \$ 4,445 | \$ 4,139 | \$ 306 | 7% |
| <i>Drug delivery</i> | | | | |
| <i>Total</i> | \$ 4,445 | \$ 4,139 | \$ 306 | 7% |

Selling and marketing expenses for the three months ended March 31, 2007 decreased 2% from the same period in the prior year when expressed in constant currency. As a percentage of net product sales, selling and marketing expenses decreased from 16% in the three months ended March 31, 2006, to 15% in the three months ended March 31, 2007.

General and Administrative Expenses

| <i>(in thousands)</i> | <i>For the Three Months Ended</i> | | <i>Change</i> | |
|---------------------------|-----------------------------------|-------------|---------------|----------|
| | <i>2007</i> | <i>2006</i> | <i>\$</i> | <i>%</i> |
| <i>Specialty generics</i> | \$ 2,275 | \$ 1,850 | \$ 425 | 23% |
| <i>Drug delivery</i> | 1,371 | 2,054 | (683) | -33% |
| <i>Total</i> | \$ 3,646 | \$ 3,904 | \$ (258) | -7% |

General and administrative expenses decreased 7% when compared to the same period in the prior year. General and administrative expenses in the first quarter of 2007 were reduced by \$215,000 as a result of a change in estimate of drug delivery management bonuses. Included in the first quarter of 2006 were strategic consulting expenses of \$412,000 related to the drug delivery business that did not recur in the first quarter of 2007. Increased general and administrative expenses in our specialty generics business include increased personnel costs and approximately \$175,000 due to fluctuations in foreign currency rates. Total general and administrative expenses as a percent of total revenues decreased to approximately 12% in the three months ended March 31, 2007, compared to approximately 14% of total revenues in the three months ended March 31, 2006.

Research and Development Expenses

| <i>(in thousands)</i> | <i>For the Three Months Ended</i> | | <i>Change</i> | |
|---------------------------|-----------------------------------|-------------|---------------|----------|
| | <i>2007</i> | <i>2006</i> | <i>\$</i> | <i>%</i> |
| <i>Specialty generics</i> | \$ 481 | \$ 494 | \$ (13) | -3% |
| <i>Drug delivery</i> | 2,194 | 2,414 | (220) | -9% |
| <i>Total</i> | \$ 2,675 | \$ 2,908 | \$ (233) | -8% |

Research and development expenses have decreased by approximately \$233,000 compared to the first quarter of 2006. Research and development expenses in the first quarter of 2007 were reduced by \$251,000 as a result of a

change in estimate of drug delivery management bonuses.

We plan to increase research and development costs as we continue to conduct our Nasulin clinical trials throughout 2007. Although cost estimates and timing of our trials are subject to change, we expect consolidated research and development expenses for 2007 to be approximately \$15,000,000 to \$16,000,000.

Table of ContentsLitigation Settlement Expenses

| <i>(in thousands)</i> | <i>For the Three Months Ended</i> | | <i>Change</i> | |
|---------------------------|-----------------------------------|-----------------------|---------------|----------|
| | <i>2007</i> | <i>March 31, 2006</i> | <i>\$</i> | <i>%</i> |
| <i>Specialty generics</i> | <i>\$</i> | <i>\$ 604</i> | <i>\$ 604</i> | <i>*</i> |

* *Not meaningful*

We incurred litigation defense costs of \$604,000 in the three months ended March 31, 2006 associated with a claim settled in 2006. See *Other liabilities* in the Notes to Condensed Consolidated Financial Statements for additional information. These amounts have been reclassified from *general and administrative expenses* on the Condensed Consolidated Income Statements.

Provision for Income Taxes

| <i>(in thousands)</i> | <i>For the Three Months Ended March 31,</i> | | | | | | | |
|---|---|----------------|-------------|----------------|--------------|----------------|-------------|----------------|
| | <i>2007</i> | | | | <i>2006</i> | | | |
| | <i>Spain</i> | <i>Ireland</i> | <i>U.S.</i> | <i>Consol.</i> | <i>Spain</i> | <i>Ireland</i> | <i>U.S.</i> | <i>Consol.</i> |
| <i>Income (loss) before income taxes</i> | \$6,468 | \$(1,304) | \$(723) | \$4,441 | \$6,898 | \$(1,282) | \$(2,069) | \$3,547 |
| <i>Provision (benefit) for income taxes</i> | 2,081 | (163) | (160) | 1,758 | 2,393 | (160) | (758) | 1,475 |
| <i>Valuation allowance</i> | | 163 | 160 | 323 | | 160 | 758 | 918 |
| <i>Net provision for income taxes</i> | 2,081 | | | 2,081 | 2,393 | | | 2,393 |
| <i>Net income (loss)</i> | \$4,387 | \$(1,304) | \$(723) | \$2,360 | \$4,505 | \$(1,282) | \$(2,069) | \$1,154 |
| <i>Effective tax rate</i> | 32% | 0% | 0% | 47% | 35% | 0% | 0% | 67% |

As a result of reporting taxable income in Spain, we recorded provisions for foreign income taxes totaling \$2,081,000 and \$2,393,000 for the three months ended March 31, 2007 and 2006, respectively. The provisions represented 32% and 35% of the pre-tax income reported in Spain of \$6,468,000 and \$6,898,000 for the three months ended March 31, 2007 and 2006, respectively. The provisions represented 47% and 67% of consolidated pre-tax income for the three months ended March 31, 2007 and 2006, respectively.

As future operating profits in the U.S and Ireland cannot be reasonably assured, no tax benefit has been recorded for the related losses, which totaled approximately \$2,027,000 and \$3,351,000 for the three months ended March 31, 2007 and 2006, respectively. Accordingly, the Company has established valuation allowances equal to the full amount of the U.S. and Irish deferred tax assets.

Should we determine that it is more likely than not that we will realize certain of our net deferred tax assets for which we have previously provided a valuation allowance, an adjustment would be required to reduce the existing valuation allowance. In addition, we operate within multiple taxing jurisdictions and are subject to audit in those jurisdictions. These audits can involve complex issues, which may require an extended period of time for resolution. No additional potential tax contingencies were considered to be probable and reasonably estimable as of March 31, 2007. However, there is the possibility that the ultimate resolution of such potential contingencies could have an adverse effect on the Consolidated Financial Statements in the future.

Table of ContentsNet Income

| <i>(in thousands, except per share data)</i> | <i>For the Three Months Ended March 31,</i> | | <i>Change</i> | |
|--|---|-------------|---------------|----------|
| | <i>2007</i> | <i>2006</i> | <i>\$</i> | <i>%</i> |
| <i>Specialty Generics</i> | \$ 3,848 | \$ 3,941 | \$ (93) | -2% |
| <i>Drug Delivery</i> | (1,488) | (2,787) | 1,299 | 47% |
| <i>Total net income</i> | \$ 2,360 | \$ 1,154 | \$ 1,206 | 105% |
| <i>Net income per common share:</i> | | | | |
| <i>Basic</i> | \$ 0.11 | \$ 0.05 | \$ 0.06 | 120% |
| <i>Diluted</i> | \$ 0.10 | \$ 0.05 | \$ 0.05 | 100% |
| <i>Weighted average common shares outstanding:</i> | | | | |
| <i>Basic</i> | 22,293 | 21,954 | 339 | 2% |
| <i>Diluted</i> | 22,534 | 23,807 | (1,273) | -5% |

We reported income from operations of \$4,220,000 in the three months ended March 31, 2007 compared to \$3,354,000 in the three months ended March 31, 2006. The combination of income from operations of \$4,220,000 and the non-operating items, primarily the provision for income taxes of \$2,081,000, resulted in net income of \$2,360,000, or \$0.11 per basic common share (\$0.10 per diluted common share) on 22,293,000 weighted average basic common shares outstanding (22,534,000 weighted average diluted common shares outstanding) in the three months ended March 31, 2007, compared to net income of \$1,154,000, or \$0.05 per basic common share (\$0.05 per diluted common share) on 21,954,000 weighted average basic common shares outstanding (23,807,000 weighted average diluted common shares outstanding) in the same period of the prior year.

LIQUIDITY AND CAPITAL RESOURCES:

Total assets increased from \$134,356,000 at December 31, 2006 to \$142,212,000 at March 31, 2007, primarily from increased cash balances. Stockholders' equity increased from \$100,331,000 at December 31, 2006 to \$104,466,000 at March 31, 2007. The increase in stockholders' equity reflects \$2,360,000 of net income generated during the quarter and the effect of fluctuations in the Euro/U.S. Dollar exchange rate, which resulted in a net increase of \$1,210,000, partially offset by a decrease of \$405,000 resulting from the implementation of FIN No. 48 on January 1, 2007.

Cash and cash equivalents increased by approximately 32% or \$5,004,000 from \$15,601,000 at December 31, 2006 to \$20,605,000 at March 31, 2007 primarily resulting from cash flows from operations totaling \$7,868,000. Our cash flows from operations were partially offset by additions to fixed assets totaling \$1,954,000, additions to drug licenses totaling \$515,000 and the repayment of borrowings totaling \$554,000. Cash and cash equivalents at March 31, 2007 include approximately \$8,896,000 of short-term liquid investments considered to be cash equivalents.

Receivables increased by approximately 2% from \$32,963,000 at December 31, 2006 to \$33,496,000 at March 31, 2007 primarily resulting from changes in foreign currency exchange rates of \$444,000. We have not experienced any material delinquencies on any of our receivables that have had a material effect on our financial position, results of operations or cash flows.

Inventory balances increased by approximately \$371,000 from \$16,279,000 at December 31, 2006 to \$16,650,000 at March 31, 2007. The increase was primarily due to increases in raw materials needed to meet projected future

demand. In addition, fluctuations in foreign currency had the effect of increasing inventories by approximately \$226,000. These increases were partially offset by a \$302,000 non-cash adjustment to write-down the U.S. generic finished goods inventory to its net realizable value.

Table of Contents

The combined total of accounts payable and accrued expenses increased from \$24,270,000 at December 31, 2006 to \$27,379,000 at March 31, 2007. The \$3,109,000 increase was primarily attributed to increased income taxes payable of approximately \$2,099,000, increased trade payables of \$1,158,000 and fluctuations in foreign currency exchange rates which increased the balances by approximately \$352,000. These increases were partially offset by a \$546,000 reclassification of the liability for uncertain tax positions to other non-current liabilities as a result of the implementation of FIN No. 48.

Operating activities for the three months ended March 31, 2007 provided net cash of \$7,868,000, which is an increase of \$6,254,000 when compared to the three months ended March 31, 2006. This change is primarily due to a \$1,206,000 increase in net income and other changes to working capital that resulted in a net increase of cash when compared to the prior year.

Investing activities for the three months ended March 31, 2007 provided net cash of \$192,000 which is an increase of \$3,995,000 when compared to the three months ended March 31, 2006. This increase is the net effect of \$1,954,000 of capital additions, primarily to our manufacturing facilities in Spain, along with \$515,000 of additions to drug licenses and related costs, offset by \$2,661,000 of proceeds from the maturity of marketable equity securities in the period.

Financing activities during the three months ended March 31, 2007 used net cash of \$554,000 for the repayment of all of the Company's short-term borrowings and long-term debt.

Seasonality. In the past, we have experienced lower sales in the third calendar quarter and higher sales in the fourth calendar quarter due to seasonality of our pharmaceutical business. The extent of such variations is dependent upon the severity of the cough, cold and flu season. As we market more pharmaceutical products whose sales are seasonal, seasonality of sales may become more significant.

Effect of Inflation and Changing Prices. Neither inflation nor changing prices has materially impacted our net product sales or income from operations for the periods presented.

Liquidity. We plan to continue making improvements to our manufacturing facilities during 2007 that include the acquisition of additional manufacturing equipment and expansion of our manufacturing facilities, in order to increase manufacturing efficiencies and accommodate our expected growth. We plan to invest \$13,000,000 to \$16,000,000 in 2007, of which we have invested \$1,954,000 in the three months ended March 31, 2007. We also plan to invest \$15,000,000 to \$16,000,000 in research and development activities in 2007, primarily to support the continued development of Nasulin, our intranasal insulin product. We plan to finance the remaining capital expenditures and research and development investments from a combination of cash flows from operations, existing cash balances and borrowings, if required. As discussed above, we have cash and cash equivalents totaling approximately \$20,605,000 as of March 31, 2007, which we believe is sufficient to fund our operations for the foreseeable future. Although the Company is generating positive cash flow from operations, (approximately \$7,868,000 in the three months ended March 31, 2007), there can be no assurance that changes in our research and development plans, capital expenditures and/or acquisitions, or other events affecting our operations will not result in the earlier depletion of our funds. We continue to search both domestically and internationally for opportunities that will enable us to continue expanding our business and explore alternative financing sources for these activities, including the possibility of public and/or private offerings of debt and equity securities. In appropriate situations, we may seek financial assistance from other sources, including contribution by others to joint ventures and other collaborative or licensing arrangements for the development, testing, manufacturing and marketing of products under development.

Critical Accounting Policies and Estimates

Our significant accounting policies are more fully described in Note 2 to our consolidated financial statements in our 2006 Form 10-K. Certain of our accounting policies are particularly important to the portrayal of our financial position, results of operations and cash flows and require the application of significant judgment by our management; as a result they are subject to an inherent degree of uncertainty. In applying those policies, our management uses its judgment to determine the appropriate assumptions to be used in the determination of certain estimates. Those estimates are based on our historical experience, terms

Table of Contents

of existing contracts, our observation of trends in the industry, information provided by our customers and information available from other outside sources, as appropriate. We have reviewed our critical accounting policies and estimated discussed in our 2006 Form 10-K and have determined that, with the exception of our critical accounting policies for the *provision for income taxes* and *inventories* noted below, those policies remain our most critical accounting policies for the quarter ended March 31, 2007. We did not make any changes to those policies during the quarter ended March 31, 2007.

Provision for income taxes

We have provided for current and deferred U.S. federal, state and foreign income taxes for the current and all prior periods presented. Current and deferred income taxes have been provided with respect to jurisdictions where certain of our subsidiaries produce taxable income. We have provided a valuation allowance with respect to the remainder of our deferred income taxes, consisting primarily of net operating loss carryforwards in the U.S. and Ireland, because of uncertainty regarding their realization. Should we determine that it is more likely than not that we will realize certain of our net deferred tax assets for which we have previously provided a valuation allowance, an adjustment would be required to reduce the existing valuation allowance.

Effective January 1, 2007, we account for uncertain tax positions in accordance with Financial Accounting Standards Board Interpretation No. 48, *Accounting for Uncertainty in Income Taxes* (FIN No. 48), an interpretation of FASB Statement No. 109, *Accounting for Income Taxes*. As a result of the implementation of FIN No. 48, we recorded a \$405,000 increase in our non-current liabilities for uncertain tax positions which was accounted for as a reduction to the January 1, 2007 balance of retained earnings. The application of income tax law is inherently complex. Income tax laws and regulations are voluminous and often ambiguous. As such, we are required to make many subjective assumptions and judgments regarding our income tax exposures. Interpretations and guidance surrounding income tax laws and regulations change frequently. Changes in our subjective assumptions and judgments could have a material effect on our financial position, results of operations or cash flows. In addition, as we operate within multiple taxing jurisdictions, we are subject to audit in those jurisdictions. The ultimate resolution of tax audits may require an extended period of time. Although we believe an adequate provision has been made for uncertain tax positions, there is the possibility that the ultimate resolution of such positions could have an adverse effect on our financial position, results of operations or cash flows. See *Provision for income taxes* in our Notes to Condensed Consolidated Financial Statements in Item 1 for additional information regarding our uncertain tax positions.

Inventories

Inventories are stated at the lower of cost or market, cost being determined on the first-in, first-out method. We analyze our inventory on a quarterly basis and write-down inventory that has a cost basis in excess of its expected net realizable value. The determination of whether or not inventory costs will be realized requires management estimates. Actual results may differ from those estimates and require inventory to be written-down, resulting in a new cost basis until sold. Reserves for slow moving or obsolete inventories are provided based on historical experience and forecasted demand.

Important Factors That May Affect Future Results

This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements appear principally in the section entitled *Management's Discussion and Analysis of Financial Condition and Results of Operations*. Forward-looking statements may appear in other sections of this report, as well. Generally, the forward-looking statements in this report include such words as *expect*, *believe*, *continue*, *anticipate*, *estimate*, *will*, *could*, *opportunity*, *future*, *project*, and similar expressions.

The forward-looking statements include statements about our:

Strategic plans;

Sales growth;

Anticipated sources of future revenues;

Table of Contents

Anticipated 2007 expenses, margins and operating performance;

Expected launch of new products;

Anticipated expenses and spending;

Planned and continuing clinical trials;

Anticipated regulatory changes and approvals; and

The sufficiency of capital resources to fund our operations.

These forward-looking statements are based on our current expectations, beliefs, assumptions, estimates, forecasts and projections for our business and the industry and markets in which we compete. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. We caution investors not to place undue reliance on the forward-looking statements contained in this report. These statements speak only as of the date of this report, and we do not undertake any obligation to update or revise them, except as required by law. We refer you to our description of the risk factors related to our business, which are contained in the section entitled *Risk Factors* in our 2006 Form 10-K. As a result of these and other factors, we may experience material fluctuations in our future operating results, which could materially affect our business, financial position, and stock price.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Foreign Currency. A substantial amount of our business is conducted in Europe and, therefore our results, which are measured in U.S. Dollars, are influenced by fluctuations in the U.S. Dollar's value in relation to other currencies, specifically the Euro. The exchange rates at March 31, 2007 and December 31, 2006 are as follows:

| U.S. Dollars per Euro | March 31, 2007 | December 31, 2006 |
|------------------------------------|---------------------------|------------------------------|
| YTD weighted average exchange rate | 1.31 | 1.26 |
| Exchange rate | 1.33 | 1.31 |

The net effect of foreign currency translation on our Condensed Consolidated Financial Statements for the three months ended March 31, 2007 was a net increase of \$1,210,000 and the cumulative historical effect as of March 31, 2007 was an increase of \$10,082,000, as reflected in our Condensed Consolidated Balance Sheets as *accumulated other comprehensive income*. The carrying values of assets and liabilities can be materially impacted by foreign currency translation, as can the translated amounts of revenues and expenses.

We have relied primarily upon financing activities to fund our operations in the U.S. In the event that we are required to fund U.S. operations or cash needs with funds generated in Europe or cash requirements in Europe with U.S. funds, currency rate fluctuations in the future could have a significant impact on us. We entered into a cash flow hedge in 2006 designed to reduce the effect of fluctuations in foreign currency on a litigation settlement liability. However, at this time, we do not anticipate altering our business plans and practices to compensate for future currency fluctuations on any other balances.

Item 4. Controls and Procedures

Bentley maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in Bentley's reports that are filed or submitted under the Securities Exchange Act of 1934, as amended (the Exchange Act) with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods required for each report and that such information is reported to Bentley's management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Table of Contents

Bentley's management carried out an evaluation, with the participation of Bentley's principal executive officer and principal financial officer, of the effectiveness of Bentley's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based on that evaluation, Bentley's principal executive officer and principal financial officer concluded that Bentley's disclosure controls and procedures were effective as of March 31, 2007.

There was no change in Bentley's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation of Bentley's internal controls that occurred during the quarter ended March 31, 2007 that has materially affected, or is reasonably likely to materially affect, Bentley's internal control over financial reporting.

PART II. OTHER INFORMATION

Item 6. Exhibits

The Exhibits filed as part of this report are listed on the Exhibit Index immediately preceding the exhibits, which Exhibit Index is incorporated herein by reference.

Table of Contents

Exhibit Index

| Exhibit Number | Description of Exhibit |
|---------------------------|---|
| 3.1 | * Restated Certificate of Incorporation of the Registrant filed with the Secretary of State of Delaware on October 29, 1999. |
| 3.2 | * Certificate of Designation of Series A Junior Participating Preferred Stock filed with the Secretary of State of Delaware on December 23, 1999. |
| 3.3 | Certificate of Amendment of Restated Certificate of Incorporation of the Registrant filed with the Secretary of State of Delaware on July 3, 2003. (Reference is made to Exhibit 3.1 to the Registrant's Form 10-Q for the quarter ended June 30, 2003, Commission File No. 1-10581, which exhibit is incorporated herein by reference.) |
| 3.4 | Certificate of Amendment of Restated Certificate of Incorporation of the Registrant filed with the Secretary of State of Delaware on July 23, 2004. (Reference is made to Exhibit 3.1 to the Registrant's Form 10-Q for the quarter ended June 30, 2004, Commission File No. 1-10581, which exhibit is incorporated herein by reference.) |
| 3.5 | Bylaws of the Registrant, as amended and restated. (Reference is made to Exhibit 3.1 to the Registrant's Form 10-Q for the quarter ended March 31, 2004, Commission File No. 1-10581, which exhibit is incorporated herein by reference.) |
| 31.1 | * Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2 | * Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1 | * Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2 | * Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| * Filed herewith. | |

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BENTLEY PHARMACEUTICALS, INC.

Registrant

May 9, 2007

By: /s/ James R. Murphy
James R. Murphy
Chairman of the Board of Directors and
Chief Executive Officer
(Principal Executive Officer)

May 9, 2007

By: /s/ Richard P. Lindsay
Richard P. Lindsay
Vice President, Chief Financial Officer,
Secretary and Treasurer
(Principal Financial Officer)